Cravath Publishes Summer 2026 Issue of Alumni Journal
Joshua Kameel focuses his practice on mergers and acquisitions, special committee representations, joint ventures, shareholder activism defense, corporate governance and general corporate matters. He also has substantial experience advising corporate clients and investment banks on a broad range of financing transactions, including both capital markets and leveraged finance transactions.
Mr. Kameel is from Los Angeles, California. He received a B.A. cum laude from the University of California, Los Angeles in 2014 and a J.D. from Columbia Law School in 2018, where he was a James Kent Scholar, a Harlan Fiske Stone Scholar and a member of the Business Law Review.
Mr. Kameel joined Cravath in 2018 and was named of counsel in 2026.
Mr. Kameel is from Los Angeles, California. He received a B.A. cum laude from the University of California, Los Angeles in 2014 and a J.D. from Columbia Law School in 2018, where he was a James Kent Scholar, a Harlan Fiske Stone Scholar and a member of the Business Law Review.
Mr. Kameel joined Cravath in 2018 and was named of counsel in 2026.
Education
-
J.D., 2018, Columbia Law School
-
B.A., 2014, University of California, Los Angelescum laude
Admitted In
- New York
Deals & Cases
September 21, 2026
DRI Healthcare’s Acquisition of Royalty Participation Rights in U.S. Net Sales of tavapadon
On September 21, 2026, DRI Healthcare Trust (“DRI Healthcare”), a pioneer in global pharmaceutical royalty monetization, announced that it has entered into purchase agreements to acquire certain royalty participation rights in U.S. net sales of tavapadon, an investigational Parkinson’s disease drug candidate, from funds managed by Bain Capital and NovaQuest Capital Management. Under the terms of the purchase agreements, DRI Healthcare will pay an aggregate purchase price of $316 million at closing. Following closing, DRI Healthcare will be entitled to receive tiered royalty payments on annual U.S. net sales of tavapadon, at combined tiered, mid‑single digit to low‑double digit royalty rates. DRI Healthcare will also be entitled to receive certain sales milestone payments upon first reaching certain cumulative U.S. net sales thresholds and four annual fixed payments of $23.4 million on the first four anniversaries of FDA approval of tavapadon. Aggregate receipts are subject to a contractual hard cap of $437.5 million. Cravath is representing DRI Healthcare in connection with the transaction.
Firm News
June 11, 2026
Cravath Announces New Of Counsels
Cravath named Aaron S. Cha and Joshua Kameel of counsels of the Firm, effective July 1, 2026.
Joshua Kameel focuses his practice on mergers and acquisitions, special committee representations, joint ventures, shareholder activism defense, corporate governance and general corporate matters. He also has substantial experience advising corporate clients and investment banks on a broad range of financing transactions, including both capital markets and leveraged finance transactions.
Mr. Kameel is from Los Angeles, California. He received a B.A. cum laude from the University of California, Los Angeles in 2014 and a J.D. from Columbia Law School in 2018, where he was a James Kent Scholar, a Harlan Fiske Stone Scholar and a member of the Business Law Review.
Mr. Kameel joined Cravath in 2018 and was named of counsel in 2026.
Mr. Kameel is from Los Angeles, California. He received a B.A. cum laude from the University of California, Los Angeles in 2014 and a J.D. from Columbia Law School in 2018, where he was a James Kent Scholar, a Harlan Fiske Stone Scholar and a member of the Business Law Review.
Mr. Kameel joined Cravath in 2018 and was named of counsel in 2026.
Education
-
J.D., 2018, Columbia Law School
-
B.A., 2014, University of California, Los Angelescum laude
Admitted In
- New York
Deals & Cases
September 21, 2026
DRI Healthcare’s Acquisition of Royalty Participation Rights in U.S. Net Sales of tavapadon
On September 21, 2026, DRI Healthcare Trust (“DRI Healthcare”), a pioneer in global pharmaceutical royalty monetization, announced that it has entered into purchase agreements to acquire certain royalty participation rights in U.S. net sales of tavapadon, an investigational Parkinson’s disease drug candidate, from funds managed by Bain Capital and NovaQuest Capital Management. Under the terms of the purchase agreements, DRI Healthcare will pay an aggregate purchase price of $316 million at closing. Following closing, DRI Healthcare will be entitled to receive tiered royalty payments on annual U.S. net sales of tavapadon, at combined tiered, mid‑single digit to low‑double digit royalty rates. DRI Healthcare will also be entitled to receive certain sales milestone payments upon first reaching certain cumulative U.S. net sales thresholds and four annual fixed payments of $23.4 million on the first four anniversaries of FDA approval of tavapadon. Aggregate receipts are subject to a contractual hard cap of $437.5 million. Cravath is representing DRI Healthcare in connection with the transaction.
Firm News
June 11, 2026
Cravath Announces New Of Counsels
Cravath named Aaron S. Cha and Joshua Kameel of counsels of the Firm, effective July 1, 2026.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.